Boston, Massachusetts 02114

  • Vestibular Diseases

Purpose:

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.


Criteria:

Inclusion Criteria: - Severe vestibular migraine (VM) Exclusion Criteria: - Neurologic or otologic disease other than VM - Psychiatric illness requiring medication - Medical illness including cancer, coronary artery or cerebrovascular disease - Known allergy to one of the test medications - Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures - Taking migraine prophylactic medication or vestibular suppressants. - Pregnant or breast feeding women


NCT ID:

NCT03578354


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02114
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.